Table 4.
Multivariable HRs for AC Use and Prostate Cancer–Specific Mortality Using Cox Proportional Hazards Regression
| Covariate | Parameter | HR | 95% CI | P |
|---|---|---|---|---|
| Aspirin* | Yes v no (referent) | 0.43 | 0.21 to 0.87 | .02 |
| AC, no aspirin* | Yes v no (referent) | 1.30 | 0.55 to 3.06 | .55 |
| Initial PSA (log) | Per ng/mL | 1.28 | 0.96 to 1.70 | .10 |
| Gleason score | 2-6 (referent) | 1.00 | — | |
| 7 | 2.53 | 1.43 to 4.48 | < .01 | |
| 8-10 | 5.89 | 3.23 to 10.7 | < .01 | |
| Clinical T stage | T1-T2a (referent) | 1.00 | — | |
| T2b-c | 3.20 | 1.91 to 5.35 | < .01 | |
| T3a-T4 | 4.25 | 1.76 to 10.2 | < .01 | |
| Treatment modality | RP (referent) | 1.00 | — | |
| RT alone | 2.12 | 1.27 to 3.53 | < .01 | |
| RT + ADT | 0.97 | 0.44 to 2.12 | .93 |
Abbreviations: AC, anticoagulant; ADT, androgen deprivation therapy; HR, hazard ratio; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiotherapy.
*
Updated as time-dependent variables.